Stockwatch: No Second Chances For Underperforming Drug Launches
Earnings Season, Coronavirus And Debt Expose Fragile Investment Propositions
Executive Summary
As the first-quarter 2020 earnings season transitions from big pharma to the long tail of smaller biotech companies, the coronavirus pandemic-related dynamics of channel stocking and greatly diminished numbers of clinic visits have magnified effects at companies with single underperforming drugs.
You may also be interested in...
Lilly Saw Pandemic-Related Benefits In Q1, Expects Headwinds Long Term
The pharma saw a $250m revenue increase due to inventory stockpiling and early prescription renewals, but its therapies outside cancer and diabetes may suffer in the coming quarters due to COVID-19.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.